1、novotech-COVID-19-Global Clinical Trial Landscape(2024)COVID-19 is a highly conta-gious infection caused by the SARS-CoV-2 virusMarketed COVID-19 drugs focus on anti-body therapies target-ing the SARS-CoV-2 spike protein(e.g.,sotrovimab)and small molecules like remde-sivir,central to COVID-19 treatm

2、entPhase III trials are advancing novel anti-body treatments(e.g.,bamlanivimab)and mRNA-based vaccines(e.g.,Modernas mR-NA-1273.529),showing promising progress in COVID-19 researchThe Asia-Pacific region has shorter median recruitment durations and faster recruitment rates than the United States and

3、 EuropeCOVID-19TRIAL CONTRIBUTIONSThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the pri

4、or written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unau

5、thorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?The United States had the highest number of COVID-19 cases in North

6、AmericaIn the Asia-Pacific region,China reported highest incidence of COVID-19 casesIn Europe,France reported a higher incidence of COVID-19In ROW,Brazil reported the highest incidence of COVID-19COVID-19GLOBAL CLINICAL TRIAL LANDSCAPE(2024)2024COVID-19 CASES777MWORLD WIDE DEATHS7.0M30%ASIA-PACIFIC5